This study is looking at a tool called Drug Response Predictor® (DRP®) to see if it can help predict which investigational cancer drugs might work best for you if you have ovarian cancer. The DRP® uses a sample of your tumor tissue to make these predictions. You may be able to join if you are a woman, at least 18 years old, have epithelial ovarian cancer that has come back within six months of platinum-based chemotherapy (platinum-resistant) or if you cannot receive platinum-based chemotherapy. You should also have received no more than one prior treatment for your platinum-resistant or platinum-ineligible disease. The main goal is to see if the DRP® can identify patients who are likely to respond to investigational cancer drugs, with results measured for up to two years.

Study design

This is an observational study, meaning researchers will collect information without giving you a specific treatment. It plans to include 60 participants.

What's involved

Your archival tumor tissue (FFPE) from your original tumor or metastatic tissue will be collected. The study does not specify any other visits, procedures, or tests.

Compensation

Not stated in the trial record.

Follow-up

The study aims to identify patients likely to be sensitive to investigational drugs, with results measured for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.